Treatment of Hyponatremia Induced by SCLC and SIADH with Wuling San and Tolvaptan

Objective: To observe the efficacy and safety of Wuling San combined with tolvaptan in the treatment of patients with hyponatremia caused by small cell lung cancer complicated by SIADH. Methods: A retrospective analysis was conducted on the clinical data of 10 patients with hyponatremia caused by small cell lung cancer complicated by SIADH. One group received tolvaptan alone, while the other group received Wuling San combined with tolvaptan. Results: The average patient age was 65.3 ± 6.6 years, with a baseline plasma sodium level of 124.6 ± 2.9 mmol/L. After three days, the Wuling San + tolvaptan group showed a significant increase to 135.2 ± 2.2 mmol/L (P < 0.05), with a correction time of 3.4 ± 1.1 days. The tolvaptan-alone group reached 133.1 ± 0.8 mmol/L (P < 0.05) in 4.8 ± 0.8 days. The correction time differed significantly between groups. No adverse events occurred in either group. Conclusion: Tolvaptan can rapidly improve blood sodium levels and overall physical condition. The addition of Wuling San may further shorten the time required to restore plasma sodium levels and could provide survival benefits for patients.